Mostrar el registro sencillo del ítem

dc.contributor.authorFaccendini, Angela
dc.contributor.authorAguzzi, Carola
dc.date.accessioned2020-06-15T12:16:43Z
dc.date.available2020-06-15T12:16:43Z
dc.date.issued2020-04
dc.identifier.citationFaccendini, A., Ruggeri, M., Miele, D., Rossi, S., Bonferoni, M. C., Aguzzi, C., ... & Ferrari, F. (2020). Norfloxacin-Loaded Electrospun Scaffolds: Montmorillonite Nanocomposite vs. Free Drug. Pharmaceutics, 12(4), 325. [doi:10.3390/pharmaceutics12040325]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/62491
dc.descriptionThe authors wish to thank Giusto Faravelli SpA for suppling the polymers.es_ES
dc.description.abstractInfections in nonhealing wounds remain one of the major challenges. Recently, nanomedicine approach seems a valid option to overcome the antibiotic resistance mechanisms. The aim of this study was the development of three types of polysaccharide-based scaffolds (chitosan-based (CH), chitosan/chondroitin sulfate-based (CH/CS), chitosan/hyaluronic acid-based (CH/HA)), as dermal substitutes, to be loaded with norfloxacin, intended for the treatment of infected wounds. The scaffolds have been loaded with norfloxacin as a free drug (N scaffolds) or in montmorillonite nanocomposite (H—hybrid-scaffolds). Chitosan/glycosaminoglycan (chondroitin sulfate or hyaluronic acid) scaffolds were prepared by means of electrospinning with a simple, one-step process. The scaffolds were characterized by 500 nm diameter fibers with homogeneous structures when norfloxacin was loaded as a free drug. On the contrary, the presence of nanocomposite caused a certain degree of surface roughness, with fibers having 1000 nm diameters. The presence of norfloxacin–montmorillonite nanocomposite (1%) caused higher deformability (90–120%) and lower elasticity (5–10 mN/cm2 ), decreasing the mechanical resistance of the systems. All the scaffolds were proven to be degraded via lysozyme (this should ensure scaffold resorption) and this sustained the drug release (from 50% to 100% in 3 days, depending on system composition), especially when the drug was loaded in the scaffolds as a nanocomposite. Moreover, the scaffolds were able to decrease the bioburden at least 100-fold, proving that drug loading in the scaffolds did not impair the antimicrobial activity of norfloxacin. Chondroitin sulfate and montmorillonite in the scaffolds are proven to possess a synergic performance, enhancing the fibroblast proliferation without impairing norfloxacin’s antimicrobial properties. The scaffold based on chondroitin sulfate, containing 1% norfloxacin in the nanocomposite, demonstrated adequate stiffness to sustain fibroblast proliferation and the capability to sustain antimicrobial properties to prevent/treat nonhealing wound infection during the healing process.es_ES
dc.description.sponsorshipThis work was partially supported by Horizon 2020 Research and Innovation Programme under Grant Agreement No 814607.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectElectrospinninges_ES
dc.subjectChitosanes_ES
dc.subjectGlycosaminoglycanses_ES
dc.subjectScaffoldses_ES
dc.subjectFibroblasts proliferationes_ES
dc.subjectAntimicrobial propertieses_ES
dc.titleNorfloxacin-Loaded Electrospun Scaffolds: Montmorillonite Nanocomposite vs. Free Druges_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doidoi:10.3390/pharmaceutics12040325


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España